CLAIMS

1. A compound represented by formula 1:



(1)

wherein

$\mathbf{R^1}$ is selected from the group consisting of H, halogen, (C_{1-4})alkyl, $O(C_{1-4})$alkyl, and haloalkyl;

$\mathbf{R^2}$ is H or Me;

$\mathbf{R^3}$ is H or (C_{1-4})alkyl;

$\mathbf{R^4}$ is H or (C_{1-4})alkyl;

$\mathbf{R^5}$ is (C_{1-4})alkyl, (C_{1-4})alkyl(C_{3-7})cycloalkyl, or (C_{3-7})cycloalkyl; and

W is selected from:



wherein,

a) one of **Y** is SO_2 and the other **Y** is $N\mathbf{R^6}$, provided that both are not the same, wherein $\mathbf{R^6}$ is selected from the group consisting of: H, $C(O)O(C_{1-4})$alkyl, (C_{1-4}) alkyl or (C_{1-4}) alkyl substituted with either a pyridinyl-N-oxide or $C(O)O\mathbf{R^8}$ wherein $\mathbf{R^8}$ is H or (C_{1-4}) alkyl; and each $\mathbf{R^9}$ is independently H or (C_{1-4}) alkyl; and

b) **E** is $C\mathbf{R^{10}R^{10}}$ wherein each $\mathbf{R^{10}}$ is independently H or (C_{1-4}) alkyl, J is CH_2 and the dotted line represents a single bond; or

c) **E** and **J** are both $C\mathbf{R^{11}}$ wherein $\mathbf{R^{11}}$ is H or (C_{1-4}) alkyl and the dotted line represents a double bond; or

W is selected from:



or



wherein,

m is 1 or 2,

$\mathbf{R}^{12}$ is H or $C_{(1-4)}$ alkyl,

$\mathbf{R}^{13}$ is H or (C_{1-4}) alkyl, and

Z is **O** or **Z** is $N\mathbf{R}^{14}$ wherein $\mathbf{R}^{14}$ is H or (C_{1-4}) alkyl; or

W is selected from a group of aromatic radicals consisting of:



,



,



,



,



and



wherein $\mathbf{R}^{15}$ is (C_{1-4}) alkyl or CF_3, and n is the integer 0, 1 or 2, or

a pharmaceutically acceptable salt, ester or a prodrug thereof.

2. The compound according to claim 1, wherein $\mathbf{R}^1$ is selected from the group consisting of: H, Cl, F, (C_{1-4}) alkyl and CF_3; $\mathbf{R}^2$, $\mathbf{R}^3$ and $\mathbf{R}^4$ is each independently H or Me; $\mathbf{R}^5$ is ethyl or cyclopropyl;

W is:



wherein **Y** is SO_2 and the other **Y** is $N\mathbf{R}^6$, provided that both are not the same, $\mathbf{R}^6$ is H, C(O)OMe, C(O)OEt, (4-pyridinyl-N-oxide)methyl, $CH_2C(O)OH$,

$CH_2C(O)OMe$, $CH_2C(O)OEt$ or $CH_2C(O)OCMe_3$, and each $\mathbf{R}^9$ is independently H or Me; or



wherein **E** is $CR^{10}R^{10}$ wherein each of $\mathbf{R}^{10}$ is independently H or Me, **J** is CH_2 and the dotted line represents a single bond; or both **E** and **J** are CR^{11} wherein $\mathbf{R}^{11}$ is H or Me and the dotted line represents a double bond; one of **Y** is SO_2 and the other **Y** is NR^6 wherein $\mathbf{R}^6$ is hydrogen or methyl; or







wherein $\mathbf{R}^{15}$ is Me or Et, and n is 0 or 1.

3. The compound according to claim 2, wherein $\mathbf{R}^{15}$ is Me.

4. The compound according to claim 3, wherein $\mathbf{R}^1$ is H, Cl, F and Me; $\mathbf{R}^2$ is H or Me;

W is:



,


,


,


,


,


, or


wherein **Y** is SO_2 and the other **Y** is NR^6, provided that both are not the same, R^6 is H, C(O)OEt, (4-pyridinyl-N-oxide)methyl, $CH_2C(O)OH$, $CH_2C(O)OMe$, $CH_2C(O)OEt$ or $CH_2C(O)OCMe_3$, and each R^9 is independently H or Me.

5. The compound according to claim 4, wherein R^3 is Me, R^6 is H, C(O)OEt or (4-pyridinyl-N-oxide)methyl, and **W** is:



or


6. The compound according to claim 4, wherein **W** is:



wherein one **Y** is SO_2 and the other **Y** is NR^6, provided that both are not the same, R^6 is H, C(O)OEt, $CH_2C(O)OH$, $CH_2C(O)OCMe_3$, (4-pyridinyl-N-oxide)methyl; and each R^9 is independently H or Me.

7. The compound according to claim 6, wherein R^6 is H and each R^9 is Me.

8. The use of a compound of formula 1 according to claim 1, for the

manufacture of a medicament for the treatment or prevention of HIV infection.

9. A pharmaceutical preparation for use in the treatment or prevention of HIV infection, wherein the active ingredient is a compound of formula 1 according to claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.

10. The use of a compound of formula 1 according to claim 1, as an anti-HIV infective.

11. A pharmaceutical composition for the treatment or prevention of HIV infection, comprising a compound of formula 1 according to claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof, in combination with a pharmaceutically acceptable carrier.

12. A method for the treatment or prevention of HIV infection, comprising administering to a patient an HIV inhibiting amount of a compound of formula 1 according to claim 1, or a pharmaceutically acceptable salt, ester or prodrug thereof.

13. A method for the treatment or prevention of HIV infection, comprising administering to a patient an HIV inhibiting amount of a pharmaceutical composition according to claim 11.

14. A process for producing a compound of formula 1 according to claim 1, comprising the step:

- coupling a compound of formula 2:



(2)

wherein **R**^{1}, **R**^{2}, **R**^{3}, **R**^{4}, and **R**^{5} are as defined in claim 1, with a phenolic derivative selected from:





wherein PG^1 is a nitrogen protecting group and PG^2 is a carboxy protecting group, said protecting groups being removable under mildly acidic, mildly alkaline or reductive conditions, and **R**^{6}, **R**^{9}, **R**^{10}, **R**^{11}, **R**^{12}, **R**^{13}, **R**^{14}, **R**^{15}, m, n, and **Z** are as

defined in claim 1.

15. The process according to claim 14, wherein said nitrogen protecting group is selected from: alkyl esters; aralkyl esters; and esters that can be cleaved by mild base treatment or mild reductive means.

16. The process according to claim 14, wherein said carboxy protecting group is selected from: Boc (*tert*-butyloxycarbonyl) and alkyl carbamates.

17. An intermediate compound of formula 2:



(2)

wherein $\mathbf{R^1}$, $\mathbf{R^2}$, $\mathbf{R^3}$, $\mathbf{R^4}$, and $\mathbf{R^5}$ are as defined in claim 1.